Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.
  • Future Medications for Obesity

    2025-05-26

    Obesity is a global health crisis affecting over 650 million people worldwide. But there's hope on the horizon. Recent breakthroughs in understanding how our gut and pancreatic hormones regulate appetite and blood sugar have led to the development of exciting new medicines to treat obesity and relat Read More
  • Drug Patent & Exclusivity Expiration Report - Week of May 26 2025

    2025-05-26

    This week, there are 11 drugs in the patent and exclusivity list. They are: - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's SPIRIVA RESPIMAT, containing active ingredient TIOTROPIUM BROMIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's COMBIVENT RESPIMAT, containing active ingredient ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's STIOLTO RESPIMAT, containing active ingredient OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's STRIVERDI RESPIMAT, containing active ingredient OLODATEROL HYDROCHLORIDE - ALNYLAM PHARMACEUTICALS INC's ONPATTRO, containing active ingredient PATISIRAN SODIUM - ACROTECH BIOPHARMA INC's FOLOTYN, containing active ingredient PRALATREXATE - SUN PHARMACEUTICAL INDUSTRIES LTD's WINLEVI, containing active ingredient CLASCOTERONE - SALIX PHARMACEUTICALS INC's XIFAXAN, containing active ingredient RIFAXIMIN - FRESENIUS KABI USA LLC's DIPRIVAN, containing active ingredient PROPOFOL Read More
  • Drug Patent & Exclusivity Expiration Report - Week of May 19 2025

    2025-05-19

    This week, there are 15 drugs in the patent and exclusivity list. They are: - TEVA PHARMACEUTICAL INDUSTRIES LTD's AIRDUO RESPICLICK, containing active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC's PROAIR RESPICLICK, containing active ingredient ALBUTEROL SULFATE - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's TRELEGY ELLIPTA, containing active ingredient FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE's BREO ELLIPTA, containing active ingredient FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's ANORO ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - AZURITY PHARMACEUTICALS INC's EDARBYCLOR, containing active ingredient AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of May 12 2025

    2025-05-12

    This week, there are 9 drugs in the patent and exclusivity list. They are: - GILEAD SCIENCES INC's ZYDELIG, containing active ingredient IDELALISIB - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's STRIVERDI RESPIMAT, containing active ingredient OLODATEROL HYDROCHLORIDE - CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES 's LYMPHOSEEK KIT, containing active ingredient TECHNETIUM TC-99M TILMANOCEPT - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's STIOLTO RESPIMAT, containing active ingredient OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - JANSSEN PHARMACEUTICALS INC's XARELTO, containing active ingredient RIVAROXABAN - CORMEDIX INC's DEFENCATH, containing active ingredient HEPARIN SODIUM; TAUROLIDINE - BIOMARIN PHARMACEUTICAL INC's KUVAN, containing active ingredient SAPROPTERIN DIHYDROCHLORIDE - MITSUBISHI TANABE PHARMA CORP's RADICAVA ORS, containing active ingredient EDARAVONE - DECIPHERA PHARMACEUTICALS LLC's QINLOCK, containing active ingredient RIPRETINIB Read More
  • Drug Patent & Exclusivity Expiration Report - Week of May 05 2025

    2025-05-05

    This week, there are 9 drugs in the patent and exclusivity list. They are: - PFIZER INC's VIZIMPRO, containing active ingredient DACOMITINIB - SUMITOMO PHARMA AMERICA INC's APTIOM, containing active ingredient ESLICARBAZEPINE ACETATE - ASTRAZENECA LP's SYMBICORT, containing active ingredient BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - NEURELIS INC's VALTOCO, containing active ingredient DIAZEPAM - NOVARTIS PHARMACEUTICAL CORP's TABRECTA, containing active ingredient CAPMATINIB HYDROCHLORIDE - ELI LILLY AND CO's RETEVMO, containing active ingredient SELPERCATINIB - BRISTOL MYERS SQUIBB CO's SPRYCEL, containing active ingredient DASATINIB - ASTRAZENECA PHARMACEUTICALS LP's BRILINTA, containing active ingredient TICAGRELOR - ELI LILLY AND CO's OLUMIANT, containing active ingredient BARICITINIB Read More
  • Kv1.3 Inhibitors: Breakthrough Treatments for Autoimmune Disorders - What You Need to Know

    2025-04-29

    The Kv1.3 channel, a classical Shaker-type potassium channel, holds a unique place in cellular biology. Unibest presents two Kv1.3 inhibitor assets, UB024 and UB029, for NewCo and License opportunities. Read More
  • Drug Briefing: Osilodrostat

    2025-04-29

    Query Drug:OlaparibQuery Time:2025-03-10 13:13:19*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Read More
  • Drug Patent & Exclusivity Expiration Report - Week of April 28 2025

    2025-04-28

    This week, there are 16 drugs in the patent and exclusivity list. They are: - PF PRISM CV's INLYTA, containing active ingredient AXITINIB - KALEO INC's AUVI-Q, containing active ingredient EPINEPHRINE - ASTRAZENECA PHARMACEUTICALS LP's BRILINTA, containing active ingredient TICAGRELOR - IPSEN BIOPHARMACEUTICALS INC's ONIVYDE, containing active ingredient IRINOTECAN HYDROCHLORIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JENTADUETO, containing active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE - BOEHRINGER INGELHEIM's GLYXAMBI, containing active ingredient EMPAGLIFLOZIN; LINAGLIPTIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's TRIJARDY XR, containing active ingredient EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's TRADJENTA, containing active ingredient LINAGLIPTIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JENTADUETO XR, containing active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of April 21 2025

    2025-04-21

    This week, there are 18 drugs in the patent and exclusivity list. They are: - VIIV HEALTHCARE CO's JULUCA, containing active ingredient DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JANSSEN PRODUCTS LP's EDURANT, containing active ingredient RILPIVIRINE HYDROCHLORIDE - GILEAD SCIENCES INC's ODEFSEY, containing active ingredient EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - VIIV HEALTHCARE CO's CABENUVA KIT, containing active ingredient CABOTEGRAVIR; RILPIVIRINE - GILEAD SCIENCES INC's COMPLERA, containing active ingredient EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - CELATOR PHARMACEUTICALS INC's VYXEOS, containing active ingredient CYTARABINE; DAUNORUBICIN - AVEO PHARMACEUTICALS INC's FOTIVDA, containing active ingredient TIVOZANIB HYDROCHLORIDE - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's ANORO ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE Read More
  • Total 15 pages  Go to Page
  • Go